產(chǎn)品描述: | ARV-825是一種BRD4抑制劑,可招募BRD4到E3泛素連接酶cereblon上,引起B(yǎng)RD4蛋白快速、有效和持續(xù)的降解,持續(xù)性下調(diào)MYC水平。 |
靶點(diǎn): |
BRD4 BD2(Cell-free assay):28 nM(Kd); BRD4 BD1(Cell-free assay):90 nM(Kd);EpigeneticReaderDomain |
體外研究: |
與其他BRD4抑制劑比較,在伯基特氏淋巴瘤細(xì)胞中,ARV-825的處理可引起c-MYC水平和下游細(xì)胞增殖和凋亡誘導(dǎo)發(fā)生更為顯著的變化。 與ARV-825共孵育72小時(shí),ARV-825對(duì)所檢測細(xì)胞系和原代AML細(xì)胞的IC50值在2-50 nM范圍內(nèi)。在AML細(xì)胞中,ARV-825可降低PIM1水平和CXCR4的磷酸化水平,而PIM1或CXCR4的過表達(dá)可逆轉(zhuǎn)該效應(yīng) |
體內(nèi)研究: |
在移植有人源白血病細(xì)胞的小鼠模型中,ARV-825實(shí)驗(yàn)組的小鼠的白血病負(fù)荷顯著低于對(duì)照組,其生存時(shí)間也較對(duì)照組長 |
細(xì)胞實(shí)驗(yàn): |
Cell lines: RS4;11細(xì)胞 Concentrations: 3, 10, 30 nM Incubation Time: 3 h Method: 用一定濃度范圍的化合物處理RS4;11細(xì)胞,孵育3小時(shí)。然后提取細(xì)胞蛋白,用特定抗體檢測蛋白表達(dá)水平。 |
動(dòng)物實(shí)驗(yàn): |
Animal Models: NOD/SCID gamma mice Dosages: 5?mg/kg Administration: i.p. |
參考文獻(xiàn): |
1. Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015, 22(6):755-63. 2. Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018, 61(2):462-481. 3. Sujan Piya, et al. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects. Blood. 2016, 128:748. 4. Chen Y, et al. Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nat Commun. 2019 Mar 22;10(1):1353. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.083 ml |
5.415 ml |
10.829 ml |
5 mM |
0.217 ml |
1.083 ml |
2.166 ml |
10 mM |
0.108 ml |
0.541 ml |
1.083 ml |
50 mM |
0.022 ml |
0.108 ml |
0.217 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |